Supplemental Table 1. The quality control parameter metrics of Oncomine Comprehensive Assay Plus

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Overall | training | test | p value |
| Number of cases | 87 | 55 | 32 |  |
| Tumor cellularity (%) (mean (SD)) | 67.52 (17.71) | 69.51 (15.16) | 64.34 (21.02) | 0.198 |
| Average base coverage depth (mean (SD)) | 2469.64 (462.08) | 2348.31 (481.15) | 2678.19 (343.58) | 0.001 |
| MAPD (mean (SD)) | 0.24 (0.06) | 0.24 (0.06) | 0.25 (0.06) | 0.359 |

SD: standard deviation, MAPD: median absolute pairwise difference

Supplemental Table 2. List of BRCA1/2 pathogenic variants

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Gene | Nucleotide change (SOPHiA) | Nucleotide change (OCA Plus) | Amino acid change (SOPHiA) | Amino acid change (OCA Plus) |
| BRCA1 | c.4186C>T | c.4186C>T | p.Gln1396\* | p.Gln1396Ter |
| BRCA2 | c.7322del | c.7322del | p.Gly244Alafs\*26 | p.Gly244AlafsTer26 |
| BRCA1 | c.3627dup | c.3627dup | p.Glu1210Argfs\*9 | p.Glu1210ArgfsTer9 |
| BRCA1 | c.922\_924delinsT | c.922\_924delAGCinsT | p.Ser308\* | p.S308X |
| BRCA2 | c.2175del | Not detected | p.Val726Phefs\*4 | Not detected |
| BRCA1 | c.4318G>T | c.4318G>T | p.Glu1440\* | p.Glu1440Ter |
| BRCA1 | c.2593\_2621del | Not detected | p.Lys865Serfs\*28 | Not detected |
| BRCA2 | c.5576\_5579del | c.5576\_5579delTTAA | p.Ile1859Lysfs\*3 | p.Ile1859LysfsTer3 |
| BRCA2 | c.6239T>G | c.6239T>G | p.Leu2080\* | p.Leu2080Ter |
| BRCA1 | c.3593T>A | c.3593T>A | p.Leu1198\* | p.Leu1198Ter |
| BRCA1 | c.922\_924delinsT | c.922\_924delAGCinsT | p.Ser308\* | p.Ser308Ter |
| BRCA2 | c.5576\_5579del | c.5576\_5579delTTAA | p.Ile1859Lysfs\*3 | p.Ile1859LysfsTer3 |
| BRCA1 | c.3503dup | Not detected | p.Asn1168Lysfs\*2 | Not detected |
| BRCA1 | c.4484+1G>T | c.4484+1G>T | NA | NA |
| BRCA1 | c.3442del | c.3442delG | p.Glu1148Argfs\*7 | p.Glu1148ArgfsTer7 |
| BRCA2 | c.8143A>T | c.8143A>T | p.Lys2715\* | p.Lys2715Ter |
| BRCA1 | c.4485-1G>T | c.4485-1G>T | NA | NA |
| BRCA1 | c.3296del | c.3296delC | p.Pro1099Leufs\*10 | p.Pro1099LeufsTer10 |
| BRCA1 | c.922\_924delinsT | c.922\_924delAGCinsT | p.Ser308\* | p.Ser308Ter |
| BRCA1 | c.3875dup | c.3875\_3876insC | p.Ala1293Cysfs\*2 | p.Ala1293CysfsTer2 |
| BRCA2 | c.6449\_6450del | c.6449\_6450delAA | p.Lys2150Serfs\*25 | p.Lys2150SerfsTer25 |
| BRCA1 | c.2062A>T | c.390C>A | p.Thr688Ser | p.Tyr130Ter |
| BRCA1 | c.4629del | c.4629delG | p.Pro1544Hisfs\*4 | p.Pro1544HisfsTer4 |
| BRCA1 | c.4986+5G>A | c.4986+5G>A | NA | NA |
| BRCA2 | c.7008-1G>T | c.7008-1G>T | NA | NA |
| BRCA2 | c.5576\_5579del | c.5576\_5579delTTAA | p.Ile1859Lysfs\*3 | p.Ile1859LysfsTer3 |
| BRCA2 | c.7516C>T | c.7516C>T | p.Gln2506\* | p.Gln2506Ter |
| BRCA2 | c.3599\_3600del | c.3599\_3600delGT | p.Cys1200\* | p.Cys1200Ter |

OCA: Oncomine Comprehensive Assay